文献速递肝病

肌肉脂肪变性在肝硬化患者中与肌少症密切相关且预后显著更差

Myosteatosis is closely associated with sarcopenia and significantly worse outcomes in patients with cirrhosis.
PubMed 文献 · J Hepatol · 2024-05-21

这项前瞻性多中心研究纳入433例肝硬化患者,用CT评估肌少症和肌肉脂肪变性。1年随访显示,合并肌少症与肌肉脂肪变性或单纯肌肉脂肪变性患者的死亡累积发生率超过无肌肉改变或单纯肌少症者的两倍。肌肉脂肪变性无论单独或合并肌少症均与更差结局相关,肌少症的预后作用应结合肌肉脂肪变性评估。

要点

  • 肝硬化患者中单纯肌肉脂肪变性166例,单纯肌少症36例,两者合并135例,无肌肉改变96例。
  • 合并肌少症与肌肉脂肪变性者1年死亡累积发生率13.8%,单纯肌肉脂肪变性者13.4%,均超过无肌肉改变者5.2%或单纯肌少症者5.6%的两倍。
  • 合并肌少症与肌肉脂肪变性者住院累积发生率显著高于无肌肉改变者,校正亚风险比1.18(95%CI 1.04-1.35)。

核心结论

  • 肌肉脂肪变性无论单独或合并肌少症在肝硬化患者中均高发,并与显著更差结局相关。
  • 肌少症的预后作用应始终结合肌肉脂肪变性的存在进行评估。

研究设计与样本

  • 前瞻性多中心研究,纳入433例肝硬化患者,用CT评估肌少症和肌肉脂肪变性,采用竞争风险分析评估1年累积发生率,并用Fine-Gray模型校正已知预后因素。

主要发现

  • 入组时单纯肌肉脂肪变性166例,单纯肌少症36例,合并肌少症与肌肉脂肪变性135例,无肌肉改变96例。
  • 合并肌少症与肌肉脂肪变性者1年死亡累积发生率13.8%,单纯肌肉脂肪变性者13.4%,无肌肉改变者5.2%,单纯肌少症者5.6%。
  • 有肌肉改变者死亡的校正亚风险比1.36(95%CI 0.99-1.86,p=0.058)。
  • 合并肌少症与肌肉脂肪变性者住院累积发生率显著高于无肌肉改变者,校正亚风险比1.18(95%CI 1.04-1.35)。
  • 合并肌少症与肌肉脂肪变性者(p=0.018)及单纯肌少症者(p=0.046)的肝失代偿累积发生率高于无肌肉改变者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Sarcopenia and myosteatosis are common in patients with cirrhosis. This study aimed to determine the prevalence of these muscle changes, their interrelations and their prognostic impact over a 12-month period. METHODS: We conducted a prospective multicentre study involving 433 patients. Sarcopenia and myosteatosis were evaluated using computed tomography scans. The 1-year cumulative incidence of relevant events was assessed by competing risk analysis. We used a Fine-Gray model adjusted for known prognostic factors to evaluate the impact of sarcopenia and myosteatosis on mortality, hospitalization, and liver decompensation. RESULTS: At enrolment, 166 patients presented with isolated myosteatosis, 36 with isolated sarcopenia, 135 with combined sarcopenia and myosteatosis and 96 patients showed no muscle changes. The 1-year cumulative incidence of death in patients with either sarcopenia and myosteatosis (13.8%) or isolated myosteatosis (13.4%) was over twice that of patients without muscle changes (5.2%) or with isolated sarcopenia (5.6%). The adjusted sub-hazard ratio for death in patients with muscle changes was 1.36 (95% CI 0.99-1.86, p = 0.058). The cumulative incidence of hospitalization was significantly higher in patients with combined sarcopenia and myosteatosis than in patients without muscle changes (adjusted sub-hazard ratio 1.18, 95% CI 1.04-1.35). The cumulative incidence of liver decompensation was greater in patients with combined sarcopenia and myosteatosis (p = 0.018) and those with isolated sarcopenia (p = 0.046) than in patients without muscle changes. Lastly, we found a strong correlation of function tests and frailty scores with the presence of muscle changes. CONCLUSIONS: Myosteatosis, whether alone or combined with sarcopenia, is highly prevalent in patients with cirrhosis and is associated with significantly worse outcomes. The prognostic role of sarcopenia should always be evaluated in relation to the presence of myosteatosis. IMPACT AND IMPLICATIONS: This study investigates the prognostic role of muscle changes in patients with cirrhosis. The novelty of this study is its multicentre, prospective nature and the fact that it distinguishes between the impact of individual muscle changes and their combination on prognosis in cirrhosis. This study highlights the prognostic role of myosteatosis, especially when combined with sarcopenia. On the other hand, the relevance of sarcopenia could be mitigated when considered together with myosteatosis. The implication from these findings is that sarcopenia should never be evaluated individually and that myosteatosis may play a dominant role in the prognosis of patients with cirrhosis.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Di Cola S, D'Amico G, Caraceni P, et al. Myosteatosis is closely associated with sarcopenia and significantly worse outcomes in patients with cirrhosis. J Hepatol. 2024. PMID: 38782120. doi:10.1016/j.jhep.2024.05.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。